Insulet (PODD): Analyst Day Shows Financial Targets Are Lofty, But Achievable - Wedbush

November 17, 2016 7:53 AM EST
Get Alerts PODD Hot Sheet
Price: $33.32 +1.68%

Rating Summary:
    15 Buy, 10 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade PODD Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Wedbush analyst, Tao Levy, reiterated his Outperform rating on shares of Insulet Corporation (NASDAQ: PODD) after attending the company's analyst day. Key Points include:

-the analyst is more confident in the the company’s ability to hit its 5-year growth targets which include organic revenue growth of 20%, gross margin of 65+%, and EBIT positive in 2018.

-diabetes franchise is expected to contribute approximately 80% of the incremental revenues over the coming 5 years

-recently hired Senior VP of Global Manufacturing and Supply Chain Operations, Charles Alpuche, laid out the key aspects behind Insulet’s path toward a 65+% gross margin

No change to the price target of $48.

For an analyst ratings summary and ratings history on Insulet Corporation click here. For more ratings news on Insulet Corporation click here.

Shares of Insulet Corporation closed at $36.57 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Management Comments

Related Entities

Tao Levy

Add Your Comment